JOIN US IN JUNE!
We have so many events coming up this month that we want to make sure you do not miss any! Below are the quick links so you can register and the detailed info is also in this newsletter.
|
|
NewYorkBIO is proud to be partnering with the New York Stock Exchange for the third Emerging Biotech Company Showcase on June 23, 2021, starting at 8:30am EDT.
The virtual Showcase brings together New York's financial community and a group of emerging biotech companies that are developing novel therapeutics and technologies that could revolutionize patient care. This year the event will include presentations from nine up and coming European biotech companies.
Click below for more information or to register!
|
|
Thank you to our sponsors: |
|
Virtual Breakfast Series
Tuesday, June 8, 9:00am
On Tuesday, we will be joined by Stephen Chambers and Gwen Cheni, partners at Indie Bio in NYC. They have pioneered the 4-month intensive incubator program and are bringing it to New York while building on their cornerstones of mentorship and community.
|
|
Stephen Chambers Bio
Stephen is Partner at IndieBio New York. He oversees relationship building between founders, investors, mentors, and partners.
Stephen was one of the founding scientists at Vertex Pharmaceuticals, working on many drug discovery programs, resulting in the FDA approval of Agenerase & Lexiva. He went on to co-founded Abpro Therapeutics, employing synthetic biology and immunology to accelerate antibody discovery and development. Recruited as CEO of SynbiCITE, the Innovation and Knowledge Center for Synthetic Biology in the UK, he oversaw a dramatic growth in the synthetic biology innovation ecosystem with a record number of startups and fundraising in this sector. At the same time, Stephen co-founded Bio-start, the UK’s first Life Science accelerator.
Stephen has co-authored over 30 peer-reviewed scientific publications, including Nature and Cell, and has several patents issued. He has been featured in Huffington Post, Upstart, BioScience, and is a regular conference speaker and government advisor on Life Science innovation and entrepreneurship.
Stephen has a Ph.D. in Molecular Biology and was recently awarded Royal Society Entrepreneur in Residence at Imperial College London. He is a Member of the Royal Society’s Industrial Fellows College and Fellow of the Royal Society of Biology.
|
|
Gwen Cheni Bio
Gwen is a Partner at IndieBio NY, advising and investing in companies at all stages of growth. Even before officially joining SOSV, Gwen was an active investor in IndieBio companies, including Tinctorium Bio/Huue, Lupa Bio/Intrinsic Medicine, and SyntheX. Gwen was a Venture Partner at Fusion Fund, an early stage fund in Palo Alto focused on AI/ML, robotics and medical devices, and a Director at Studio X, a machine learning venture studio based in Austin. Gwen spent 3 years with Singularity University Ventures, an impact-focused accelerator, and helped launch their first batch of startups in the Nordic campus. Prior to venture, Gwen spent 18 years on Wall Street investing in public equities, started her career at Goldman Sachs, JPMorgan, and promoted to portfolio manager at a $300 million innovation-themed hedge fund.
Gwen is bilingual in computer science programming languages and wet lab research protocols. On the computer science side, she received her bachelor’s degree in math/economics with a minor in computer science electrical engineering. One of her four business school MBA concentrations was econometrics/statistical learning. She has completed all sixteen machine learning certification courses offered by DeepLearning.ai. On the wet lab biology side, Gwen spent 2 years at UCSF researching immunotherapy (CAR-T) for glioblastomas, and was second author on two publications. She spent summers researching x-ray protein crystallography, nitric oxide as an oncology therapeutic, and image recognition of breast cancer histology.
Gwen is a Chartered Financial Analyst charterholder. She currently sits on the Advisory Board of the Yale University School of Medicine.
|
|
Exciting news from member company Taconic Biosciences. Their new TruIMPORT(TM) solution is part of the model generation alliance with Cyagen Biosciences for nonprofit researchers. It allows researchers to import their animal models without quarantine which is an issue for many researchers when importing from China. |
|
We're bringing together moderators and panelists for a webinar series this June, focused on bringing staff back into work places. |
|
June 8 | From Ideation to Creation: The Path of an Academic Pharma Innovation
Some of the most innovative ideas in healthcare come right from the halls of academic medical centers. But do these ideas have what it takes to be successful in the market? Join us on June 8th to get a glimpse into the road to success. RSVP
June 9 | Building Better Teams Through Diversity
The session will be an interactive and open conversation, allowing you the opportunity to offer up your impressions and questions with the objective of gaining a more clear and nuanced understanding of diversity in the workplace. RSVP
June 22 | Digital Therapeutics and the Future of Medicine
Join us as we welcome experts in the space to discuss the opportunities and challenges of potential digital solutions from a variety of perspectives, and how large players in the ecosystem are looking towards the future. RSVP
June 30 | Neuroimmunology: Potential for Novel Therapeutics for CNS Disorders
Given the advances in this field, Johnson & Johnson Innovation, in collaboration with Janssen Neuroscience, is seeking to gather industry-leading entrepreneurs, biotechs and academic researchers for a discussion on harnessing the next wave of science and innovation in neuroimmunology. RSVP
|
|
 |
Got News?
Have something you'd like us to feature in the newsletter?
|
|
|
|
|
|
|
|
|
